C WorldWide Group Holding A S Has $31.75 Million Position in Royalty Pharma PLC $RPRX

C WorldWide Group Holding A S lowered its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 5.5% in the first quarter, Holdings Channel.com reports. The firm owned 661,776 shares of the biopharmaceutical company’s stock after selling 38,685 shares during the period. Royalty Pharma comprises approximately 0.7% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 21st largest position. C WorldWide Group Holding A S’s holdings in Royalty Pharma were worth $31,745,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. LM Advisors LLC purchased a new position in shares of Royalty Pharma during the fourth quarter valued at $26,000. Blue Trust Inc. lifted its stake in Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 437 shares in the last quarter. Lloyd Advisory Services LLC. acquired a new stake in Royalty Pharma during the 4th quarter worth about $30,000. Private Trust Co. NA boosted its position in Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares during the period. Finally, Bessemer Group Inc. grew its stake in Royalty Pharma by 34.7% during the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 282 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Up 3.9%

Shares of Royalty Pharma stock opened at $58.53 on Friday. The firm has a market cap of $33.70 billion, a price-to-earnings ratio of 39.82, a P/E/G ratio of 9.97 and a beta of 0.43. The stock has a 50-day simple moving average of $54.86 and a 200-day simple moving average of $48.46. Royalty Pharma PLC has a 52-week low of $34.08 and a 52-week high of $58.84. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The firm had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. On average, equities research analysts expect that Royalty Pharma PLC will post 5.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of research reports. UBS Group upped their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. increased their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Finally, Morgan Stanley boosted their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, Royalty Pharma presently has a consensus rating of “Buy” and a consensus target price of $56.57.

Insider Buying and Selling at Royalty Pharma

In other news, EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $56.52, for a total transaction of $5,652,000.00. Following the transaction, the executive vice president owned 459,399 shares in the company, valued at $25,965,231.48. This represents a 17.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 9,099 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total transaction of $508,452.12. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 427,800 shares of company stock valued at $23,333,723. 18.84% of the stock is currently owned by insiders.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.